+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 99Years
All Genders
ID07264647

Phase 2 Study of Neoadjuvant Chemo-immunotherapy with Tislelizumab for Adults with Stage III PD-L1 Positive Non-Small Cell Lung Cancer

Led by Fondazione Ricerca Traslazionale · Updated on 2025-12-04

30

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment approach for adults who are current or former smokers diagnosed with stage III non-small cell lung cancer NSCLC that is positive for PD-L1 and does not have specific genetic alterations EGFR, ALK, ROS1, RET. This phase 2, single-arm study aims to assess the use of neoadjuvant chemo-immunotherapy to improve treatment outcomes in this group of patients. Participants will receive three cycles of neoadjuvant chemo-immunotherapy tailored to their NSCLC type. Following this treatment, their disease will be reassessed with imaging and pathological evaluation of lymph nodes. Patients whose lymph nodes show no remaining cancer may undergo surgery followed by up to one year of maintenance treatment with the drug tislelizumab. Those with persistent lymph node involvement will receive chemoradiotherapy as standard care. Throughout the study, patients will undergo comprehensive assessments including chest CT, PET-CT, brain MRI, and pathological evaluations before and after neoadjuvant therapy. Researchers will monitor the success of surgery and disease status over three years, focusing on complete tumor removal. Safety and effectiveness of the treatment approach will be tracked during follow-up, which includes adjuvant therapy and routine clinical care.

CONDITIONS

Brief Title

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

Research Team

F

Federico Cappuzzo, Medical Oncology

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here